stage

AIN
PE Investment 5-10x

PE Investment 5-10x

location_on Geneva ,  Switzerland

Please note:
Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. This platform is targeted solely at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. Investors are encouraged to review and evaluate the investments and determine at their own discretion, the appropriateness of making the particular investment. The information on this website is provided for informational purposes only, but we cannot guarantee that the information is accurate or complete. We strongly encourage investors to complete their own due diligence with licensed professionals, prior to making any investment and will not offer any legal or tax advice.

Short Summary

Exclusive co-investment opportunity alongside large institutions - operating at a 89% success rate, with 6 exits in the last 18 months.

Series A - Precision Oncology - Cancer Treatment - £14m valuation pre-commercialisation. Expecting a 5-10x return

Highlights

  • Proven track record in BioTech with a 7x return and 19x return in 2025
  • 100 year track record
  • 175 active investments, over 25 IPOs
  • Exclusive - Private Equity Investment - 5-10X Return with 89% success rate

Overview

Target $3,900,000
Minimum $55,000
Investment Raised $1,700,000
Previous Rounds $0
Stage Other
Investor Role Any

Ask a question
Got a question about this project?

Similar Projects

Loading…
Loading the web debug toolbar…
Attempt #